Bio-Rad Laboratories, Inc.
BIO
$251.15
$0.140.06%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -2.00% | 2.79% | -6.26% | -9.75% | -6.73% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -2.00% | 2.79% | -6.26% | -9.75% | -6.73% |
| Cost of Revenue | 3.42% | -0.88% | -11.26% | -9.56% | -5.21% |
| Gross Profit | -6.66% | 6.02% | -1.87% | -9.92% | -8.01% |
| SG&A Expenses | -1.53% | -0.33% | -5.69% | -6.68% | -0.72% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.98% | 8.17% | -9.00% | -9.09% | -3.46% |
| Operating Income | -38.97% | -29.16% | 11.77% | -16.32% | -22.87% |
| Income Before Tax | -312.17% | 528.45% | -85.70% | 478.90% | -60.74% |
| Income Tax Expenses | -345.49% | 575.79% | -83.57% | 575.38% | -70.15% |
| Earnings from Continuing Operations | -304.67% | 514.71% | -86.32% | 456.71% | -57.75% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -304.67% | 514.71% | -86.32% | 456.71% | -57.75% |
| EBIT | -38.97% | -29.16% | 11.77% | -16.32% | -22.87% |
| EBITDA | -26.48% | -19.45% | 8.89% | -8.82% | -16.68% |
| EPS Basic | -310.48% | 540.07% | -92.62% | 477.75% | -56.44% |
| Normalized Basic EPS | -36.80% | -31.05% | 16.28% | -23.26% | -16.48% |
| EPS Diluted | -310.69% | 541.21% | -92.62% | 479.74% | -56.32% |
| Normalized Diluted EPS | -36.75% | -30.85% | 16.28% | -22.92% | -16.25% |
| Average Basic Shares Outstanding | -2.76% | -3.96% | -3.27% | -3.64% | -3.00% |
| Average Diluted Shares Outstanding | -2.84% | -4.24% | -3.27% | -4.07% | -3.28% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
